Cargando…

Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies

The persistence and reactivity of CAR T cells were enhanced by adding co‐stimulatory domains, which is the basis of currently approved CAR‐T cell therapies. However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti‐CD19 CA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shohdy, Kyrillus S., Pillai, Manon, Guest, Ryan, Rothwell, Dominic, Kirillova, Natalia, Chow, Shien, Gilham, David, Thistlethwaite, Fiona, Hawkins, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435680/ https://www.ncbi.nlm.nih.gov/pubmed/37601889 http://dx.doi.org/10.1002/jha2.731

Ejemplares similares

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial
por: Evans, Manon, et al.
Publicado: (2014)

Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis
por: Owen, Kathryn, et al.
Publicado: (2022)

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
por: Thistlethwaite, Fiona C., et al.
Publicado: (2017)

Prognostic Impact of Cytotoxic CD4 T Cells in Tumor Immune Microenvironment of Patients with Breast Cancer
por: Shohdy, Kyrillus S., et al.
Publicado: (2021)

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
por: Kueberuwa, Gray, et al.
Publicado: (2018)

Alopecia Universalis Associated with Ulcerative Colitis and The Role of Azathioprine
por: Shohdy, Kyrillus S, et al.
Publicado: (2018)

Engineering T cells for cancer therapy
por: Mansoor, W, et al.
Publicado: (2005)

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023)

Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
por: Pillai, Manon, et al.
Publicado: (2020)

CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity
por: Kueberuwa, Gray, et al.
Publicado: (2017)

CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas
por: Baur, Katharina, et al.
Publicado: (2023)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
por: Chow, Shien, et al.
Publicado: (2014)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL
por: Tan, Yue, et al.
Publicado: (2021)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?
por: Kassem, Loay, et al.
Publicado: (2019)

Availability of Informal Caregivers for Palliative Care Patients with Cancer: Is there a Difference between Higher- and Lower-Income Settings
por: Abdel-Malek, Raafat, et al.
Publicado: (2019)

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
por: Cao, Xuanqi, et al.
Publicado: (2022)

HIV and immunotherapy: will CAR-T cell therapy cure HIV?
por: Veeraraghavan, Vishnu P., et al.
Publicado: (2023)

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL
por: Qiu, Yan, et al.
Publicado: (2023)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro
por: Liu, Ming, et al.
Publicado: (2023)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
por: Ma, Yunju, et al.
Publicado: (2023)

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
por: Liu, Shuangyou, et al.
Publicado: (2020)

Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)
por: Cesaro, Simone, et al.
Publicado: (2023)

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
por: Xiang, Jingyu, et al.
Publicado: (2023)

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
por: Dreger, Peter, et al.
Publicado: (2022)

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
por: Huang, Qiusha, et al.
Publicado: (2023)

Motor Cars for Civil Surgeons
Publicado: (1908)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
por: Loureiro, L. R., et al.
Publicado: (2018)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
por: Fang, Karen Kai-Lin, et al.
Publicado: (2023)

Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
por: Yang, Fan, et al.
Publicado: (2022)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_01pv9np8u7o9s0a548r0ojps7r